With a strong foundation in RNA interference technology, Silexion Therapeutics develops innovative RNA-based therapeutics designed to silence specific genes involved in pancreatic cancer growth and metastasis.

2 days ago · Silexion Therapeutics Corp. New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically ...

1 day ago · Silexion's latest preclinical findings mark a significant advancement in RNAi therapeutics, with data showing 50% tumor growth reduction and complete necrosis in half of treated tumors after 30 ...

Silexion Therapeutics, known for its pioneering work in RNAi therapies, has previously achieved promising results in a Phase 2 trial with its first-generation product, LODER™, for non-resectable ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company...

3 days ago · Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise. Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.

Jan 16, 2025 · Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS...